Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
Eli Lilly (LLY) and Hims & Hers (HIMS) partnered to sell obesity medicines Zepbound and Foundayo on HIMS's platform. Patients can receive prescriptions and have medicines shipped directly. Pricing starts at $149/month for Foundayo and $299/month for Zepbound. The deal aims to expand access and streamline the process for patients.
How this was made
The 30-second read
Why it matters
The collaboration could increase sales volumes for Lilly's GLP‑1 drugs and diversify Hims & Hers' revenue streams, potentially influencing investor sentiment in both stocks.
Market read
First‑report partnership that may affect pricing dynamics and market share in the fast‑growing obesity‑drug market.
What to watch
Regulatory scrutiny of direct‑to‑consumer drug sales and pricing competition from compounded alternatives.
Background
Eli Lilly, a leading pharma company, and Hims & Hers, a telehealth platform, have formalized a distribution agreement for obesity medicines.
Ticker impact
Eli Lilly announced a new partnership with Hims & Hers to sell its obesity drugs Zepbound and Foundayo via the Hims & Hers platform.
likely modest upside as market prices in incremental sales opportunity
Partnership opens a large digital health platform to Lilly's obesity drugs, but impact depends on patient uptake and pricing.
Hims & Hers entered an agreement with Eli Lilly to offer Zepbound and Foundayo directly on its telehealth platform.
potential upward pressure as investors value new pharma revenue stream
Access to Lilly's obesity drugs could increase transaction volume and improve unit economics for Hims & Hers.
Market effects
May boost the broader digital‑health and obesity‑drug sectors as more players consider similar partnerships.
U.S. market sees added exposure to GLP‑1 therapies through a consumer platform.
Highlights trend of pharma leveraging telehealth channels worldwide.
Counterpoint
If patient adoption is slower than expected, the partnership could dilute margins and pressure both stocks.
Key entities
- companyEli Lilly and Company
Pharmaceutical manufacturer of Zepbound and Foundayo.
- companyHims & Hers Health, Inc.
Digital health platform offering telehealth services.
